Lifestyle changes, meds effective to prevent or delay Type 2
Findings from the multicenter, U.S. Diabetes Prevention Program Outcomes Study (DPPOS) detail the 21-year follow-up of more than 3,200 adults with prediabetes who had participated in the original Diabetes Prevention Program trial.

The DPPOS confirmed that treatment through lifestyle interventions or the medication metformin were effective long-term in preventing or delaying the development of Type 2 diabetes among adults with prediabetes compared to the participants who received standard care.

However, the study participants’ risk of having a heart attack, stroke or dying from cardiovascular disease over the 21-year study period did not differ in the metformin or lifestyle intervention groups compared to the standard care group.

The number of heart attacks, strokes or deaths related to cardiovascular disease was relatively low despite development of Type 2 diabetes in more than 50% of study participants. This may be attributable to the mildness of the diabetes and widespread use of medications for blood pressure or cholesterol that also reduce the risk of cardiovascular disease.